

## A study of the role of serotonin in the anxiolytic effect of nitrous oxide in rodents

Dimitris E. Emmanouil<sup>a</sup>, Z. Papadopoulou-Daifoti<sup>b</sup>, Philip T. Hagihara<sup>c</sup>,  
Daniel G. Quock<sup>c</sup>, Raymond M. Quock<sup>c,\*</sup>

<sup>a</sup> Department of Paediatric Dentistry, School of Dental Medicine, University of Athens, Athens, Greece

<sup>b</sup> Department of Pharmacology, School of Medicine, University of Athens, Athens, Greece

<sup>c</sup> Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, P.O. Box 646534, Pullman, WA 99164-6534, Pullman, Washington, U.S.A.

Received 26 May 2005; received in revised form 9 May 2006; accepted 18 May 2006

Available online 7 July 2006

### Abstract

**Rationale:** In earlier studies, we have shown that nitrous oxide (N<sub>2</sub>O)-induced behavioral effects in rats and mice are mediated by benzodiazepine receptors.

**Objectives:** This two-part study was conducted in order to investigate the possible role of serotonin (5-HT) in the behavioral effects of N<sub>2</sub>O by clarifying its effects on regional brain concentrations of 5-HT and assessing the influence of 5-HT antagonist and reuptake inhibiting drugs on the anxiolytic-like behavioral effect of N<sub>2</sub>O.

**Methods:** In experiment A, male, 150–200 g Sprague–Dawley rats were killed following a 15-min exposure to room air or 70% N<sub>2</sub>O. The frontal cortex, hippocampus, corpus striatum and hypothalamus were dissected out and analyzed by HPLC with electrochemical detection for content of 5-HT and 5-hydroxyindoleacetic acid (5-HIAA); dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) were also measured. In experiment B, male 18–22 g NIH Swiss mice were pretreated with the 5-HT<sub>2</sub> antagonist cinanserin, the 5-HT<sub>3</sub> antagonist LY-278,584, the 5-HT reuptake inhibitor fluoxetine or saline and tested in the light/dark exploration test under 70% N<sub>2</sub>O 30 min after pretreatment.

**Results:** In experiment A, N<sub>2</sub>O produced differential effects on 5-HT neurons in distinct brain areas. There was increased 5-HT turnover in the hypothalamus, decreased turnover in the frontal cortex but no changes in either hippocampus or corpus striatum. By comparison, dopamine turnover in these brain regions was unaltered by N<sub>2</sub>O exposure. In experiment B, pretreatment with neither cinanserin, LY-278,584 nor fluoxetine had any appreciable effect on the N<sub>2</sub>O-induced increase in time spent in the light compartment. Only cinanserin significantly reduced the N<sub>2</sub>O-induced increase in transitions.

**Conclusions:** While neurochemical results suggest an effect of N<sub>2</sub>O on brain 5-HT function, there was no effect of 5-HT<sub>2</sub> or 5-HT<sub>3</sub> antagonists or 5-HT reuptake inhibitor on N<sub>2</sub>O-induced anxiolytic-like behavior.

© 2006 Elsevier Inc. All rights reserved.

**Keywords:** Nitrous oxide; Anxiety; 5-Hydroxytryptamine; HPLC quantification of brain monoamines; Light/dark exploration test; Rats; Mice

### 1. Introduction

Nitrous oxide (N<sub>2</sub>O) is the oldest anesthetic gas available and continues to be widely used in combination with other anesthetics for production of surgical anesthesia and, either alone or in combination, for production of conscious sedation in dentistry (Jackson and Johnson, 2002; Paterson and Tahmas-

sebi, 2003). The mechanism of its analgesic effect is thought to involve opioid receptors as the analgesia in human subjects is at least partly reversed by the opioid receptor blocker naloxone (Chapman and Benedetti, 1979; Gillman et al., 1980; Yang et al., 1980). This is consistent with reports that N<sub>2</sub>O-induced antinociception in experimental animals is antagonized by opioid receptor blockers (Quock and Vaughn, 1995). The mechanism of its anxiolytic effect in humans is uncertain, although research in animal models of experimental anxiety has implicated benzodiazepine receptors in the reduction in anxiety

\* Corresponding author. Tel.: +1 509 345 5956; fax: +1 509 335 5902.

E-mail address: [raymondq@uic.edu](mailto:raymondq@uic.edu) (R.M. Quock).

(Quock et al., 1992, 1993; Emmanouil et al., 1994; Li and Quock, 2001).

The current pharmacological management of anxiety focuses on brain mechanisms involving benzodiazepine and 5-hydroxytryptamine (5-HT) receptors. The current research was conducted to ascertain whether 5-HT receptors might also be involved in the anxiolytic effect of N<sub>2</sub>O. Towards this end, one study (experiment A) was conducted in rats to determine the influence of N<sub>2</sub>O exposure on brain monoamine levels, and another study (experiment B) was conducted in mice to determine the influence of 5-HT receptor antagonists and reuptake inhibitors on N<sub>2</sub>O-induced behavioural effects.

## 2. Materials and methods

### 2.1. Experiment A

The objective of this experiment was to determine the influence of a 15-min exposure upon 5-HT, dopamine (DA) and their respective metabolites, 5-hydroxyindoleacetic acid (5-HIAA) and 3,4-dihydroxyphenylacetic acid (DOPAC), in the frontal cortex, hippocampus, corpus striatum and hypothalamus.

#### 2.1.1. Animals

Male Sprague–Dawley rats, weighing 150–200 g, were purchased from Sasco Inc. (Omaha, NE) for this research. After an acclimatization period of 7 days, animals were randomly assigned to one of the following two groups: group I, rats ( $n=10$ ) were exposed to 70% N<sub>2</sub>O mixed with 30% oxygen for 15 min; group II, control rats ( $n=10$ ) were exposed to room air for 15 min. These experiments were approved by an institutional animal care and use committee and carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 80-23, revised 1996).

#### 2.1.2. Exposure to nitrous oxide

Rats were exposed in pairs to nitrous oxide inside a medium-size AtmosBag<sup>®</sup> glove bag (Aldrich, Milwaukee, WI). The sealed glove bag was filled with compressed air or a mixture of N<sub>2</sub>O and O<sub>2</sub> (all medical grade, Rockford Industrial Gas, Rockford, IL) via a length of polyethylene tubing using a portable N<sub>2</sub>O/O<sub>2</sub> dental sedation system (Porter, Hatfield, PA). The total gas inflow rate was 10 l/min (either 10 l/min compressed air or 7 l/min N<sub>2</sub>O+3 l/min O<sub>2</sub>). The atmosphere inside the glove bag was confirmed by a POET II<sup>®</sup> anaesthetic monitoring system (Criticare, Milwaukee, WI).

#### 2.1.3. HPLC quantification of brain monoamines

After 15 min, the glove bag was opened, and the rats were quickly removed and sacrificed by decapitation. The brains were dissected on ice, and the striatum, frontal cortex, hypothalamus and hippocampus were removed. The tissue samples were immediately frozen in liquid nitrogen and stored at  $-80^{\circ}\text{C}$  until assayed. 5-HT, 5-HIAA, DA and DOPAC were measured by high performance liquid chromatography (HPLC)

with electrochemical detector (ECD), as described by Sharp et al. (1987) with some minor modifications (Papadopoulou-Daifoti et al., 1995). After weighing, the dissected tissues were homogenized and deproteinized in 500  $\mu\text{l}$  of 0.2 N perchloric acid solution containing 7.9 mM Na<sub>2</sub>S<sub>2</sub>O<sub>5</sub> and 1.3 mM Na<sub>2</sub>EDTA. The homogenate was centrifuged at 37,000 $\times g$  for 30 min and the supernatant was stored at  $-80^{\circ}\text{C}$ . A reverse-phase ion pair chromatography was used in all analyses. The mobile phase consisted of an acetonitrile–50 mM phosphate buffer (10.5:91.5) pH 3.0, containing 5-octylsulfate sodium salt (300 mg/l) as the ion-pair reagent and (20 mg/l) Na<sub>2</sub>EDTA. Reference standards were prepared in 0.2 N perchloric acid solution containing 7.9 mM Na<sub>2</sub>S<sub>2</sub>O<sub>5</sub> and 1.3 mM Na<sub>2</sub>EDTA. The sensitivity of the assays was always tested using external standards and an HPLC system BAS-LC4B with an amperometric detector. The working electrode was glassy carbon, the columns were Thermo Hypersil-Keystone<sup>™</sup> 150 $\times$ 2.1 mm, 5  $\mu\text{m}$  Hypersil, Elite C18 (Thermo Electron, Cheshire, UK), and the HPLC system was connected to a computer. Samples were quantified by comparison of the areas under peaks with those of reference standards using HPLC software (Chromatography Station for Windows<sup>™</sup>, Watrex International, Inc., San Francisco, CA). Additionally, the ratios of serotonin (5-HIAA/5-HT) and dopamine (DOPAC/DA) were calculated as indices of the serotonin and dopamine turnover rates which reflect the serotonergic and dopaminergic activity, including release and/or metabolism function (Cransac et al., 1996; Connor et al., 1997).

#### 2.1.4. Statistical analysis of data

Tissue levels of 5-HT, 5-HIAA, DA and DOPAC as well as ratios of 5-HIAA/5-HT and DOPAC/DA in control and N<sub>2</sub>O-exposed groups of rats were compared using Student's *t*-test following testing for normality and equal variance.

### 2.2. Experiment B

The objective of this experiment was to determine the influence of blockade of selected 5-HT receptor subtypes and inhibition of 5-HT reuptake on N<sub>2</sub>O-induced anxiolytic-like behavioural response to N<sub>2</sub>O in the mouse light/dark exploration test.

#### 2.2.1. Animals

Male NIH Swiss mice, 18–22 g body weight, were purchased from Harlan Laboratories (Indianapolis, IN) and used in these experiments, which were approved by an institutional animal care and use committee. Mice were housed five per cage in the Wegner Hall Vivarium with access to food and water ad libitum. The facility is maintained on a 12-h light/dark cycle (lights on 0700, lights off 1900) under standard conditions ( $22\pm 1^{\circ}\text{C}$  room temperature, 33% humidity). Mice were kept in the holding room for at least 4 days following arrival in the facility. Each animal was used only once and then discarded.

#### 2.2.2. Apparatus

The light/dark exploration box (450 mm length $\times$ 270 mm width $\times$ 270 mm height) was constructed of acrylic (Abbott

Plastics, Rockford, IL). An acrylic divider with a 75×75 mm opening at floor level divided the box into a light compartment (three-fifths of the total length) and a dark compartment (two-fifths of the total length). The walls of the light and dark compartments were made of black and white acrylic, respectively. Behavioural observations and assessments were generally performed between 1000 and 1400 h. During all experiments, the light compartment was illuminated by two 40-W white light fluorescent tubes mounted 180 mm directly overhead. In this paradigm, animals were individually placed in the center of the light compartment of the box, facing away from the divider, and then observed for 5 min. The time spent in the light chamber of the box as well as the number of transitions between the light and dark compartments were recorded for each mouse. A mouse was considered to have entered the new area when all four legs crossed the threshold into the compartment.

### 2.2.3. Drugs

The following drugs were used in this experiment: N<sub>2</sub>O and O<sub>2</sub> (both medical grade, A&L Welding, Spokane, WA), LY-278,584 maleate (1-methyl-*N*-(8-methyl-8-azabicyclo[3.2.1]-oct-3-yl)-1*H*-indazole-3-carboxamide maleate, Research Biochemicals International, Inc., Natick, MA), and cinanserin hydrochloride and fluoxetine hydrochloride (Tocris Cookson, Inc., Ellisville, MO).

N<sub>2</sub>O and O<sub>2</sub> were delivered into the light/dark box via a length of polyethylene tubing using a portable N<sub>2</sub>O/O<sub>2</sub> dental sedation system (Porter, Hatfield, PA). The gases were delivered in a 7:3 proportion in a total inflow rate of 10 l/min (i.e., 7.0 l/min N<sub>2</sub>O+3.0 l/min O<sub>2</sub>=70% N<sub>2</sub>O in O<sub>2</sub>). A POET II<sup>®</sup> anaesthetic monitoring system was used to ascertain that the

desired atmosphere of N<sub>2</sub>O and O<sub>2</sub> were attained within the filling time.

LY-278,584, cinanserin and fluoxetine were prepared in 0.9% physiological saline and administered intraperitoneally at doses of 1.0, 2.5 and 10 mg/kg, respectively, in a volume of 0.1 ml/10 g body weight. Pretreatment drug doses were determined in preliminary experiments. N<sub>2</sub>O and O<sub>2</sub> control groups received the same volume of vehicle (0.9% physiological saline). LY-278,584, cinanserin and fluoxetine pretreatment times were all 30 min prior to testing.

### 2.2.4. Statistical analysis of data

The mean behavioral endpoints for N<sub>2</sub>O in groups of mice in the absence and presence of LY-278,584 and fluoxetine were analyzed by two-way analysis of variance (ANOVA) and post hoc Bonferroni test. Due to a non-normal distribution, the influence of cinanserin pretreatment on N<sub>2</sub>O effects was analyzed by Kruskal–Wallis non-parametric ANOVA.

## 3. Results

### 3.1. Experiment A

The neurochemical results show that a 15-min exposure to 70% N<sub>2</sub>O caused differential changes in 5-HT and 5-HIAA concentrations in different brain regions (Fig. 1). In the hypothalamus, there was a 23% increase in levels of 5-HIAA but not 5-HT, increasing the ratio of 5-HIAA/5-HT from 1.53 to 1.83 ( $p < 0.05$ ). In the frontal cortex, there was a 26% increase in amounts of 5-HT but not 5-HIAA, decreasing the ratio of 5-HIAA/5-HT from 0.92 to 0.83 ( $p > 0.05$ ). In the hippocampus, there were inappreciable effects of N<sub>2</sub>O on 5-HT and 5-HIAA




Fig. 1. Comparison of DA, DOPAC, 5HT and 5HIAAA concentrations in the hypothalamus (upper left panel), frontal cortex (upper right panel), hippocampus (lower left panel) and frontal cortex (lower right panel) of compressed air (solid bars)- and N<sub>2</sub>O (shaded bars)-exposed rats. Each bar represents the mean and vertical lines the S.E.M. of 10 rats per group. Significance of difference: \* $p < 0.05$  compared to room air exposure.




Fig. 2. The influence of pretreatment with cinanserin (CIN) on N<sub>2</sub>O-induced anxiolytic-like behavior in the light/dark exploration test: time in light compartment (left) and number of transitions (right). Each bar represents the mean and vertical lines the S.E.M. of 10–20 mice per group. Significance of difference: \* $p < 0.05$  compared to saline (SAL) control group; # $p < 0.05$  compared to N<sub>2</sub>O group.

concentrations, and the ratio of 5-HIAA/5-HT changed from 0.68 to 0.69 ( $p > 0.05$ ). In the corpus striatum, there were also inconsequential changes in levels of 5-HT and 5-HIAA, and the ratio of 5-HIAA/5-HT was decreased slightly from 1.33 to 1.28 ( $p > 0.05$ ).

The HPLC results also showed that exposure to 70% N<sub>2</sub>O had no significant effect on either DA or DOPAC in the hypothalamus, frontal cortex, corpus striatum or hippocampus.

### 3.2. Experiment B

In the behavioural experiments, exposure to N<sub>2</sub>O caused significant increases in both time spent in the light compartment ( $p < 0.05$ ) and the number of transitions ( $p < 0.05$ ). Pretreatment with cinanserin had no influence on the N<sub>2</sub>O-induced increase in time ( $p > 0.05$ ) but did significantly attenuate the N<sub>2</sub>O-induced increase in transitions ( $p < 0.05$ ) (Fig. 2).

Pretreatment with LY-278,584 did not alter the effects of N<sub>2</sub>O on increasing the time spent in the light compartment and the number of transitions in the light/dark exploration test (Fig. 3). A two-way ANOVA (factor N<sub>2</sub>O × factor LY) was used to analyze the data [time spent in the light compartment:  $F_{N_2O}(1,62) = 9.98$ ,  $p < 0.005$ ;  $F_{LY}(1,62) = 0.09$ ,  $p > 0.05$ ;  $F_{N_2O \times LY}(1,62) = 0.28$ ,  $p > 0.05$ ; number of transitions:  $F_{N_2O}(1,62) = 28.78$ ,  $p < 0.0001$ ;  $F_{LY}(1,62) = 0.51$ ,  $p > 0.05$ ;  $F_{N_2O \times LY}(1,62) = 0.27$ ,  $p > 0.05$ ].




Fig. 3. The influence of pretreatment with LY-278,584 (LY) on N<sub>2</sub>O-induced anxiolytic-like behavior in the light/dark exploration test: time in light compartment (left) and number of transitions (right). Each bar represents the mean and vertical lines the S.E.M. of 10–20 mice per group. Significance of difference: \* $p < 0.05$  compared to saline (SAL) control group.

Pretreatment with FLX had no influence on the effects of N<sub>2</sub>O on increasing the time spent in the light compartment and the number of transitions in the light/dark exploration test (Fig. 4). A two-way ANOVA (factor N<sub>2</sub>O × factor FLX) was used to analyze the data [time spent in the light compartment:  $F_{N_2O}(1,66) = 8.71$ ,  $p < 0.01$ ;  $F_{FLX}(1,66) = 0.29$ ,  $p > 0.05$ ;  $F_{N_2O \times FLX}(1,66) = 1.33$ ,  $p > 0.05$ ; number of transitions:  $F_{N_2O}(1,66) = 28.82$ ,  $p < 0.0001$ ;  $F_{FLX}(1,66) = 0.54$ ,  $p > 0.05$ ;  $F_{N_2O \times FLX}(1,66) = 0.03$ ,  $p > 0.05$ ].

## 4. Discussion

Our laboratory was the first to report striking similarities in behavioural response and pharmacological interactions between N<sub>2</sub>O and benzodiazepines in animal models of experimental anxiety (Quock et al., 1987, 1992, 1993; Czech and Quock, 1993; Emmanouil et al., 1994; Li and Quock, 2001). These findings support the idea that N<sub>2</sub>O can mimick in some way the action of benzodiazepines at binding sites that are coupled to GABA<sub>A</sub> receptors forming the chloride ion channel (Zorumski and Isenberg, 1991).

The above conclusion notwithstanding, it has also long been recognized that 5-HT plays a crucial role in the regulation of anxiety (Gorman et al., 2002). It is plausible that N<sub>2</sub>O may exert a direct or indirect action upon 5-HT neurotransmission in producing its anxiolytic effect. Previously, it was demonstrated




Fig. 4. The influence of pretreatment with fluoxetine (FLX) on N<sub>2</sub>O-induced anxiolytic-like behavior in the light/dark exploration test: time in light compartment (left) and number of transitions (right). Each bar represents the mean and vertical lines the S.E.M. of 10–20 mice per group. Significance of difference: \* $p < 0.05$  compared to saline (SAL) control group.

that N<sub>2</sub>O-induced antinociception was enhanced by blockade of 5-HT<sub>1C</sub> and/or 5-HT<sub>2</sub> receptors and antagonized by blockade of 5-HT<sub>3</sub> receptors (Mueller and Quock, 1992).

#### 4.1. Experiment A

While there appear to be many investigations of the influence of N<sub>2</sub>O on regional brain levels of the catecholamines norepinephrine and dopamine (Abdul-Kareem et al., 1991; Murakawa et al., 1994a; Kofke et al., 1995; Karuri et al., 1998; Turle et al., 1998), there have been few studies of the effect of N<sub>2</sub>O on brain 5-HT.

A 15-min exposure to 70% N<sub>2</sub>O induced a significant increase in the 5-HIAA/5-HT ratio in hypothalamus which reflects an increased serotonergic activity. In particular, this increase was due to increased 5-HIAA levels. An increase in 5-HIAA and/or 5-HIAA/5-HT ratio suggests increased 5-HT activity, because the increase in metabolite tissue levels *ex vivo* and/or the increase in metabolite/neurotransmitter ratio reflect increased neurotransmitter activity *in vivo* (Shannon et al., 1986; Thorre et al., 1997). On the other hand, a 15-min exposure to 70% N<sub>2</sub>O induced a significant decrease of 5-HIAA/5-HT ratio in the cerebral cortex, which was attributed to increased 5-HT tissue content without any effect on the 5-HIAA content. The differential effects of N<sub>2</sub>O indicate that serotonergic neurons are differentially affected by exposure to N<sub>2</sub>O in distinct brain areas. It has been suggested that central 5-HT plays a key role in the etiology of anxiety (Handley, 1995; Pellow and File, 1986). In the neurochemical studies, it was reported that changes in the content of 5-HT and its turnover rate in the brain are associated with anxiogenesis (Iversen, 1984; Chaouloff et al., 1998).

Serotonergic synapses are most densely concentrated in limbic regions including the amygdala and bed nucleus of the stria terminalis (BNST), thought to play a seminal role in anxiety (Davis, 1998), as well as the ventral striatum and hypothalamus. There are much less dense but not insignificant concentrations in cortical regions as measured by serotonin transporter binding in humans and non-human primates (Smith et al., 1999).

The limbic system contains dense serotonergic projections. Studies of fear conditioning have shown that 5-HT inhibits

cortical and thalamic excitatory drive into lateral nucleus of the amygdala that is critical in fear conditioning (LeDoux, 1998). These authors conclude that increased 5-HT may decrease the sensitivity of the amygdala to activating (particularly aversive) stimuli (Stutzmann et al., 1998). Others have shown in an *in vitro* amygdala slice preparation that 5-HT mediates this inhibition primarily via activation of 5-HT<sub>2</sub> receptors on inhibitory interneurons within basolateral amygdala (Rainnie, 1999).

Serotonin has many electrophysiologic functions in its target areas (Aghajanian, 1995), and the combination of excitatory, inhibitory and modulatory roles lead to a complex electrophysiology that can be summed up as potentiating gating. Cortical modulation by 5-HT is mediated by multiple excitatory and inhibitory receptors. There seems to be a complicated dose–response relationship in cortical circuitry modulated by 5-HT. In some cases, moderate levels of 5-HT are needed to potentiate glutamatergic action, but higher 5-HT levels lead to inhibition (Aghajanian, 1995). Although its role in cortical processing is complex (Buhot, 1997), its importance is clearly implicated by the serotonergic modulation by hallucinogens (e.g., LSD and mescaline) and atypical antipsychotics (e.g., clozapine, quetiapine).

The rise in 5-HT content in cerebral cortex, seen after exposure to 70% N<sub>2</sub>O, suggests that the predominant effect of N<sub>2</sub>O under our experimental conditions was to modify the neuronal activity possibly by inhibiting its own release at the level of presynaptic 5-HT<sub>1A</sub> autoreceptors (Pineyro and Blier, 1999). However, the cortical effects of N<sub>2</sub>O did not seem to be generalized to hypothalamus, thus showing a regional specificity of N<sub>2</sub>O effects on serotonergic neurons. Hypothalamic modulation by 5-HT may be involved in appetite control, modulation of the HPA stress response and sexual behavior (Rainnie, 1999). More detailed neurochemical studies are needed to elucidate the mechanism by which N<sub>2</sub>O exerts its anxiolytic activity through the central serotonergic neuron.

No significant differences in the levels of dopamine were reported. A previous report indicated alterations in steady-state levels of DA but not of NE in the brains of rats exposed to 75% N<sub>2</sub>O for 4 h. However, a 2 h exposure did not alter either DA or NE levels (Karuri et al., 1998). Variations in methodology, including the method of sacrifice (microwave killing vs.

decapitation), may have contributed to these differences; it is, therefore, difficult to compare the results of our study with that report.

#### 4.2. Experiment B

Following the identification of 5-HT receptor subunits (Glennon et al., 1995), there has been a major research endeavour to determine the roles of these in mediating anxiety and anxiolytic drug effect. We decided to directly test for 5-HT involvement by assessing the interaction between N<sub>2</sub>O and 5-HT receptor blocking and reuptake inhibitor drugs.

There are earlier reports that 5-HT<sub>2</sub> receptors in the periaqueductal gray matter subserve negative reinforcement and that 5-HT<sub>2</sub> antagonists can suppress this central aversive system (Jenck et al., 1989). 5-HT<sub>2</sub> antagonists can relieve anxiety (Deakin, 1988; Raheja et al., 1995). The 5-HT<sub>1C</sub>/5-HT<sub>2</sub> antagonist mianserin was reported to be effective in significantly reducing the anxiogenic-like behaviour observed in mice following withdrawal from ethanol (Lal et al., 1993). However, the 5-HT<sub>2</sub> agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane (DOI) was also reported to elicit a strong anxiolytic effect comparable to that of benzodiazepines (Nic Dhonnchadha et al., 2003; Ripoll et al., 2005).

Consistent with earlier results (Emmanouil et al., 1994), exposure to 70% N<sub>2</sub>O significantly increased the amount of time spent by mice in the light compartment of the light/dark box and the number of transitions made by mice between the light and dark compartments of the box. The increase in time spent in the light compartment reflects an anxiolytic-like behavioural response to N<sub>2</sub>O. The increase in transitions is related to a locomotor stimulatory effect of N<sub>2</sub>O in response to indirect activation of opioid receptors (Hynes and Berkowitz, 1979). There is an apparent involvement of brain dopamine in the locomotor response to N<sub>2</sub>O (Dorris and Truong, 1993; Hynes and Berkowitz, 1983).

In the present study, selective blockade of 5-HT<sub>2</sub> receptors with cinanserin had no effect on the N<sub>2</sub>O-induced increase in time spent in the light compartment but did significantly attenuate the N<sub>2</sub>O-induced increase in number of intercompartmental transitions. As the time spent in the light compartment is a more critical index of anxiolytic-like activity, these findings would dissociate 5-HT<sub>2</sub> receptors in the behavioural response to N<sub>2</sub>O.

Other research has implicated 5-HT<sub>3</sub> receptors in anxiety, although this remains controversial. N<sub>2</sub>O has been reported to modulate 5-HT<sub>3</sub> receptor activity (Yamakura and Harris, 2000; Suzuki et al., 2002), and 5-HT<sub>3</sub> antagonists have been reported to produce anxiolytic-like behavioural responses in a wide range of animal tests (Tyers et al., 1987; Jones et al., 1988; Costall and Naylor, 1992, 2004; Costall et al., 1993). However, other laboratories were unable to replicate these findings (Johnston and File, 1988; File and Johnston, 1989). A number of clinical studies also reported that 5-HT<sub>3</sub> antagonists are generally ineffective in reducing anxiety (Schweizer and Rickels, 1991; Wilde and Markham, 1996; Olivier et al., 2000).

In our experiments, the blockade of 5-HT<sub>3</sub> receptors with LY-278,584 (Fludzinski et al., 1987) failed to influence the

anxiolytic-like behavioural response of N<sub>2</sub>O in the light/dark exploration test, suggesting that 5-HT<sub>3</sub> receptors are perhaps not involved in the behavioural response to N<sub>2</sub>O. This is consistent with an earlier report that blockade of 5-HT<sub>3</sub> receptors failed to reduce PAG stimulation-induced aversive behaviour (Jenck et al., 1989).

LY-278,584 also failed to reduce the number of intercompartmental transitions. This is in agreement with earlier reports that 5-HT<sub>3</sub> receptors do not play a role in regulating spontaneous locomotor activity (Kelley et al., 2003; Hodge et al., 2004) and 5-HT<sub>3</sub> antagonists have no appreciable effect on locomotor activity (Jones et al., 1988).

An additional experiment was conducted using the selective 5-HT reuptake inhibitor fluoxetine. If N<sub>2</sub>O promotes the release of 5-HT to activate 5-HT<sub>2</sub> receptors, inhibiting the reuptake of 5-HT would be expected to enhance the anxiolytic-like response to N<sub>2</sub>O. However, the behavioural effect of N<sub>2</sub>O was unaffected by fluoxetine in doses previously shown to inhibit 5-HT reuptake. It is not known whether inhibition of 5-HT in specific brain regions rather than globally might influence the behavioural response to N<sub>2</sub>O.

Brain 5-HT is widely distributed, is seemingly involved in numerous physiological regulatory mechanisms and may potentially participate in counteracting mechanisms. Part of the diversity of functions of 5-HT is likely due to the fact that effects of 5-HT are mediated by as many as 13 distinct seven-transmembrane-spanning, G-protein-coupled receptors (GPCRs) and at least one ligand-gated ion channel (Hoyer et al., 2002). The multiplicity of 5-HT receptors and their unique distribution in the limbic system suggest that more brain region- or pathway-specific analysis of 5-HT function may be required for a more complete answer to the question of whether 5-HT mechanisms are involved in the anxiolytic effect of N<sub>2</sub>O.

In summary, acute exposure of rats to 70% N<sub>2</sub>O significantly elevated 5-HT turnover in the hypothalamus, decreased turnover in the frontal cortex but no changes in either hippocampus or corpus striatum. While cognizant of potential species differences in drug effect, we found that the N<sub>2</sub>O-induced increase in time spent in the light compartment was unaltered by 5-HT<sub>2</sub> or 5-HT<sub>3</sub> receptor blockade or inhibition of 5-HT reuptake and the N<sub>2</sub>O-induced increase in transitions was sensitive to antagonism by 5-HT<sub>2</sub> receptor blockade but not 5-HT<sub>3</sub> receptor blockade or inhibition of 5-HT reuptake.

#### Acknowledgements

This research was supported by NIH Grants DE-09378 and DA-10343. We are thankful to Dr. Shuang Li (University of Washington, Seattle, Washington) for her assistance with the statistical analysis.

#### References

- Abdul-Kareem HS, Sharma RP, Drown DB. Effects of repeated intermittent exposures to nitrous oxide on central neurotransmitters and hepatic methionine synthetase activity in CD-1 mice. *Toxicol Ind Health* 1991;7:97–108.

- Aghajanian G. Electrophysiology of serotonin receptor subtypes and signal transduction pathways. In: Bloom F, Kupfer D, editors. *Psychopharmacology: the fourth generation of progress*. New York: Raven Press; 1995. p. 451–60.
- Buhot M. Serotonin receptors in cognitive behaviors. *Curr Opin Neurobiol* 1997;7:243–54.
- Chapman CR, Benedetti C. Nitrous oxide effects on cerebral evoked potential to pain: partial reversal with a narcotic antagonist. *Anesthesiology* 1979;51:135–8.
- Chaouloff F, Aguerre S, Mormede P. GR 127935 and (+)-WAY 100135 do not affect TFMPP-induced inhibition of 5-HT synthesis in the midbrain and hippocampus of Wistar–Kyoto rats. *Neuropharmacology* 1998;37:1159–67.
- Connor TJ, Kelly JP, Leonard BE. Forced swim test-induced neurochemical endocrine, and immune changes in the rat. *Pharmacol Biochem Behav* 1997;58:961–7.
- Costall B, Naylor RJ. Anxiolytic potential of 5HT<sub>3</sub> receptor antagonists. *Pharmacol Toxicol* 1992;70:157–62.
- Costall B, Naylor RJ. 5HT<sub>3</sub> receptors. *Curr Drug Targets CNS Neurol Disord* 2004;3:27–37.
- Costall B, Domeney AM, Kelly ME, Tomkins DM, Naylor RJ, Wong EH, et al. The effect of the 5HT<sub>3</sub> receptor antagonist, RS-42358-197, in animal models of anxiety. *Eur J Pharmacol* 1993;234:91–9.
- Cransac H, Cottet-Emard JM, Pequignot JM, Peyrin L. Monoamines (norepinephrine, dopamine, serotonin) in the rat medial vestibular nucleus: endogenous levels and turnover. *J Neural Transm* 1996;103:391–401.
- Czech DA, Quock RM. Nitrous oxide induces an anxiolytic-like effect in the conditioned defensive burying paradigm, which can be reversed with a benzodiazepine receptor blocker. *Psychopharmacology* 1993;113:211–6.
- Davis M. Are different parts of the extended amygdala involved in fear vs. anxiety. *Biol Psychiatry* 1998;44:1239–47.
- Deakin JF. 5HT<sub>2</sub> receptors, depression and anxiety. *Pharmacol Biochem Behav* 1988;29:819–20.
- Dorris RL, Truong V. Locomotor effects of nitrous oxide in mice: requirement of newly-synthesized and main intraneuronal storage pools of dopamine. *J Pharm Pharmacol* 1993;45:315–6.
- Emmanouil DE, Johnson CH, Quock RM. Nitrous oxide anxiolytic effect in mice in the elevated plus maze: mediation by benzodiazepine receptors. *Psychopharmacology* 1994;115:167–72.
- File SE, Johnston AL. Lack of effects of 5HT<sub>3</sub> receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in the rat. *Psychopharmacology* 1989;99:248–51.
- Fludzinski P, Evrard DA, Bloomquist WE, Lacefield WB, Pfeifer W, Jones ND, et al. Indazoles as indole bioisosteres: synthesis and evaluation of the tropanyl ester and amide of indazole-3-carboxylate as antagonists at the serotonin 5HT<sub>3</sub> receptor. *J Med Chem* 1987;30:1535–7.
- Gillman MA, Kok L, Lichtigfeld FJ. Paradoxical effect of naloxone on nitrous oxide analgesia in man. *Eur J Pharmacol* 1980;61:175–7.
- Glennon RA, Dukat M, Westkaemper RB. Serotonin receptor subtypes and ligands. In: Bloom FE, Kupfer D, editors. *Psychopharmacology: the fourth generation of progress*. New York: Raven Press; 1995.
- Gorman JM, Hirschfeld RM, Ninan PT. New developments in the neurobiological basis of anxiety disorders. *Psychopharmacol Bull* 2002;36(Suppl 2):49–67.
- Handley SL. 5-Hydroxytryptamine pathways in anxiety and its treatment. *Pharmacol Ther* 1995;66:103–48.
- Hodge CW, Kelley SP, Bratt AM, Iller K, Schroeder JP, Besheer J. 5-HT<sub>3A</sub> receptor subunit is required for 5-HT<sub>3</sub> antagonist-induced reductions in alcohol drinking. *Neuropsychopharmacology* 2004;29:1807–13.
- Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. *Pharmacol Biochem Behav* 2002(April);71(4):533–54.
- Hynes MD, Berkowitz BA. Nitrous oxide stimulation of locomotor activity: evidence for an opiate-like behavioral effect. *J Pharmacol Exp Ther* 1979;209:304–8.
- Hynes MD, Berkowitz BA. Catecholamine mechanisms in the stimulation of mouse locomotor activity by nitrous oxide and morphine. *Eur J Pharmacol* 1983(May 20);90(1):109–14.
- Iversen SD. 5-HT and anxiety. *Neuropharmacology* 1984;23:1553–60.
- Jackson DL, Johnson BS. Inhalational and enteral conscious sedation for the adult dental patient. *Dent Clin North Am* 2002;46:781–802.
- Jenck F, Broekkamp CL, Van Delft AM. Effects of serotonin receptor antagonists on PAG stimulation induced aversion: different contributions of 5HT<sub>1</sub>, 5HT<sub>2</sub> and 5HT<sub>3</sub> receptors. *Psychopharmacology* 1989;97:489–95.
- Johnston AL, File SE. Effects of 5HT<sub>3</sub> antagonists in two animal tests of anxiety. *Neurosci Lett* 1988;32:S44.
- Jones BJ, Costall B, Domeney AM, Kelly ME, Naylor RJ, Oakley NR, et al. The potential anxiolytic activity of GR38032F, a 5HT<sub>3</sub>-receptor antagonist. *Br J Pharmacol* 1988;93:985–93.
- Kelley SP, Bratt AM, Hodge CW. Targeted gene deletion of the 5-HT<sub>3A</sub> receptor subunit produces an anxiolytic phenotype in mice. *Eur J Pharmacol* 2003;461:19–25.
- Kofke WA, Stiller RL, Rose ME. Comparison of extracellular dopamine concentration in awake unstressed and postsurgical nitrous oxide sedated rats. *J Neurosurg Anesthesiol* 1995;7:280–3.
- Karuri AR, Kugel G, Engelking LR, Kumar MS. Alterations in catecholamine turnover in specific regions of the rat brain following acute exposure to nitrous oxide. *Brain Res Bull* 1998;45:557–61.
- Lal H, Prather PL, Rezazadeh SM. Potential role of 5HT<sub>1C</sub> and/or 5HT<sub>2</sub> receptors in the mianserin-induced prevention of angiogenic behaviors occurring during ethanol withdrawal. *Alcohol Clin Exp Res* 1993;17:411–7.
- LeDoux J. Fear and the brain: where have we been, and where are we going? *Biol Psychiatry* 1998;44:1229–38.
- Li S, Quock RM. Comparison of N<sub>2</sub>O- and chlordiazepoxide-induced behaviors in the light/dark exploration test. *Pharmacol Biochem Behav* 2001;68:789–96.
- Mueller JL, Quock RM. Contrasting influences of 5-Hydroxytryptamine receptors in nitrous oxide antinociception in mice. *Pharmacol Biochem Behav* 1992;41:429–32.
- Murakawa M, Adachi T, Nakao S, Seo N, Shingu K, Mori K. Activation of the cortical and medullary dopaminergic systems by nitrous oxide in rats: a possible neurochemical basis for psychotropic effects and postanesthetic nausea and vomiting. *Anesth Analg* 1994;78:376–81.
- Nic Dhonnchadha BA, Bourin M, Hascoet M. Anxiolytic-like effects of 5-HT<sub>2</sub> ligands on three mouse models of anxiety. *Behav Brain Res* 2003;140:203–14.
- Olivier B, van Wijngaarden I, Soudijn W. 5HT<sub>3</sub> receptor antagonists and anxiety: a preclinical and clinical review. *Eur Neuropsychopharmacol* 2000;10:77–95.
- Papadopoulou-Daifoti Z, Antoniou K, Vamvakidis A, Kalliteraki I, Varonos DD. Neurochemical changes in dopamine and serotonin turnover rate in discrete regions of rat brain after the administration of glycinergic compounds. *Acta Ther* 1995;21:5–18.
- Paterson SA, Tahmassebi JF. Paediatric dentistry in the new millennium: 3. Use of inhalation sedation in paediatric dentistry. *Dent Update* 2003;30(358):350–6.
- Pellow S, File SE. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. *Pharmacol Biochem Behav* 1986;24:525–9.
- Pineyro G, Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. *Pharmacol Rev* 1999;51:534–91.
- Quock RM, Emmanouil DE, Vaughn LK, Pruhs RJ. Benzodiazepine receptor mediation of behavioral effects of nitrous oxide in mice. *Psychopharmacology* 1992;107:310–4.
- Quock RM, Vaughn LK. Nitrous oxide: mechanism of its analgesic action. *Analgesia* 1995;1:151–9.
- Quock RM, Wojcechowskyj JA, Emmanouil DE. Comparison of nitrous oxide, morphine and diazepam effects in the mouse staircase test. *Psychopharmacology* 1987;92:324–6.
- Quock RM, Wetzel PJ, Maillefer RH, Hodges BH, Curtis BA, Czech DA. Benzodiazepine receptor-mediated behavioral effects of nitrous oxide in the rat social interaction test. *Pharmacol Biochem Behav* 1993;46:161–5.
- Raheja RK, Bharwani I, Penetrante AE. Efficacy of risperidone for behavioral disorders in the elderly: a clinical observation. *J Geriatr Psychiatry Neurol* 1995;8:159–61.
- Rainnie D. Serotonergic modulation of neurotransmission in the rat basolateral amygdala. *J Neurophysiol* 1999;82:69–85.

- Ripoll N, Nic Dhonnchadha BA, Sebille V, Bourin M, Hascoet M. The four-plates test–retest paradigm to discriminate anxiolytic effects. *Psychopharmacology (Berl)* 2005;180:73–83.
- Schweizer E, Rickels K. Serotonergic anxiolytics: a review of their clinical efficacy. In: Rodgers RJ, Cooper SJ, editors. *5-HT<sub>1A</sub> Agonists, 5-HT<sub>3</sub> antagonists and benzodiazepines: their comparative behavioural pharmacology*. Chichester: John Wiley and Sons Ltd; 1991. p. 365–76.
- Sharp T, Zetterstrom T, Series HG, Carlsson A, Grahame-Smith DG, Ungerstedt U. HPLC-EC analysis of catechols and indoles in rat brain dialysates. *Life Sci*. 1987;41:869–72.
- Shannon NJ, Gunnet JW, Moore KE. A comparison of biochemical indices of 5-hydroxytryptaminergic neuronal activity following electrical stimulation of the dorsal raphe nucleus. *J Neurochem* 1986;47:958–65.
- Smith H, Daunais J, Nader M, Porrino L. Distribution of [<sup>3</sup>H]citalopram binding sites in the nonhuman primate brain. *Ann NY Acad Sci* 1999;877:700–2.
- Stutzmann G, McEwen B, LeDoux J. Serotonin modulation of sensory inputs to the lateral amygdala: dependency on corticosterone. *J Neurosci* 1998;18:9529–38.
- Suzuki T, Koyama H, Sugimoto M, Uchida I, Mashimo T. The diverse actions of volatile and gaseous anesthetics on human-cloned 5hydroxytryptamine<sub>3</sub> receptors expressed in *Xenopus* oocytes. *Anesthesiology* 2002;96:699–704.
- Thorre K, Chaouloff F, Sarre S, Meensen R, Ebinger G, Michotte Y. Differential effects of restraint stress on hippocampal 5-HT metabolism and extracellular levels of 5-HT in streptozotocin-diabetic rats. *Brain Res* 1997;772:209–16.
- Turle N, Saget A, Zouani B, Risso JJ. Neurochemical studies of narcosis: a comparison between the effects of nitrous oxide and hyperbaric nitrogen on the dopaminergic nigrostriatal pathway. *Neurochem Res* 1998;23:997–1003.
- Tyers MB, Costall B, Domeney AM, Jones BJ, Kelly ME, Naylor RJ, et al. The anxiolytic activities of 5HT<sub>3</sub> antagonists in laboratory animals. *Neurosci Lett* 1987;29:S68.
- Wilde MI, Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. *Drugs* 1996;52:773–94.
- Yamakura T, Harris RA. Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels. *Anesthesiology* 2000;93:1095–101.
- Yang JC, Clark WC, Ngai SH. Antagonism of nitrous oxide analgesia by naloxone in man. *Anesthesiology* 1980;52:414–7.
- Zorumski CF, Isenberg KE. Insights into the structure and function of GABA-benzodiazepine receptors: ion channels and psychiatry. *Am J Psychiatry* 1991;148:162–73.